Simcha Therapeutics is a clinical-stage biopharmaceutical company in New Haven, Connecticut that uses directed evolution to engineer next-generation cytokine immunotherapies for cancer. Its lead program, ST-067, is a first-in-class 'decoy-resistant' interleukin-18 (IL-18) variant engineered to evade the natural decoy protein (IL-18BP) that tumors exploit to silence the immune system. Spun out of Aaron Ring's lab at Yale School of Medicine and backed by $40M in Series B financing, Simcha is advancing ST-067 through Phase 1/2 trials in solid tumors and partnering with Janssen to armor CAR T cell therapies.
CREW Carbon is a Yale-spinout water and climate technology company based in Hamden, Connecticut. It retrofits municipal and industrial wastewater treatment plants with a closed-system enhanced-weathering process: dosing alkaline minerals into wastewater to convert dissolved CO2 into stable bicarbonate. The approach lowers operating costs and improves treatment performance for utilities while permanently and measurably removing atmospheric carbon, which it sells to corporate buyers as durable carbon removal credits.